ALNY vs PHAT
ALNY: Alnylam is a pioneer in RNA interference (RNAi) therapeutics, using gene-silencing technology to treat rare genetic diseases and cardiovascular conditions. PHAT: Phathom Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative treatments for gastrointestinal diseases, anchored by its potassium-competitive acid blocker platform.
Side-by-side fundamentals
| Metric | ALNY | PHAT | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $205.52 | $8.75 | |
| Market cap as of 2026-08-03 | $27.5B | $708M | |
| P/E as of 2026-08-03 | 34.98 | n/a | |
| PEG as of 2026-08-03 | 0.75 | n/a | |
| Net margin as of 2026-08-03 | +16.8% | -76.8% | ALNY higher |
| Gross margin as of 2026-08-03 | +79.7% | +84.9% | PHAT higher |
| Operating margin as of 2026-08-03 | +19.9% | -47.5% | ALNY higher |
| ROE as of 2026-08-03 | +93.6% | -232.8% | ALNY higher |
| ROA as of 2026-08-03 | +15.8% | -59.7% | ALNY higher |
| Debt / equity as of 2026-08-03 | 2.02 | 12.38 | ALNY lower |
| Revenue growth (YoY) as of 2026-08-03 | +95.1% | +150.3% | PHAT higher |
| Revenue CAGR (3y) SEC XBRL | +53.0% | n/a | |
| Beta as of 2026-08-03 | 0.71 | 1.11 | |
| 1-year return as of 2026-07-31 close | -47.6% | +2.5% | PHAT higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.